Gene therapy for adults with Pompe disease
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests a one-time gene therapy (AB-1009) for adults with late-onset Pompe disease. It aims to see if the treatment is safe and improves muscle and breathing function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been on enzyme replacement therapy (like Lumizyme or Nexviazyme) for at least 6 months and had at least 10 infusions.
- Your lung function (FVC) is between 30% and 80% of what's expected for your age.
- You can walk at least 100 meters with or without a cane or walker.
- You do not need a breathing machine during the day, and you have not had gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new gene therapy for adults with late-onset Pompe disease who have already tried enzyme replacement therapy (ERT). The goal is to see if the gene therapy is safe and can help improve muscle strength and breathing.
This trial tests a new gene therapy for late-onset Pompe disease. The therapy aims to help your body produce the enzyme needed to break down glycogen, which may improve muscle and breathing function.
This trial tests if getting enzyme replacement therapy every 4 weeks instead of every 2 weeks is safe and effective for stable adults with late-onset Pompe disease. It may reduce the burden of frequent infusions.
This study tests an experimental drug (S-606001) for people with late-onset Pompe disease. It aims to see if the drug can improve breathing and walking ability. You cannot have had enzyme replacement therapy for at least 3 months before joining.
This trial tests a new drug, DNL952, in adults with late-onset Pompe disease. It aims to see if the drug is safe and how it works in the body, with different groups for people currently on enzyme replacement therapy or those who haven't had it in the past year.
This trial tests how well a new enzyme treatment (cipaglucosidase alfa with miglustat) works and how safe it is in children and babies with infant-onset Pompe disease. It may help by improving muscle function after earlier treatment or, for some babies, starting treatment when no prior enzyme therapy has been given.
Hear when a new Pompe Disease (Late-onset) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.